Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec reports positive Adentri results

Biogen Idec reports positive Adentri results

15th August 2007

Biogen Idec has announced positive results of its phase II clinical study of Adentri in stable heart failure patients.

Presented in the current issue of the Journal of the American College of Cardiology, the study showed that patients administered with Adentri for ten days in conjunction with standard therapy for heart failure exhibited preserved renal function while displaying clinically significant increases in sodium excretion.

Adentri is an orally-administered A1 adenosine receptor antagonist that was also well tolerated in the trial.

Barry H Greenberg, professor of medicine and director of the advanced heart failure programme at the University of California, said: “We are excited to have these data published showing the potential of Adentri in patients with heart failure

“Worsening kidney function occurs commonly in these patients and it is typically associated with adverse outcomes.”

He added that the results of the trial saw significant increases in patients’ excretion of salt, without their renal function being significantly affected, suggesting that the compound could potentially improve the current standard of care for the condition.

Last month, Biogen Idec signed a partnership agreement with Cardiokine relating to the development of lixivatapan as a treatment for hyponatremia in congestive heart failure patients.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.